Skip to main content

Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial.

Publication ,  Journal Article
Bhattacharya, R; Uddin, MM; Patel, AP; Niroula, A; Finneran, P; Bernardo, R; Fitch, KV; Lu, MT; Bloomfield, GS; Malvestutto, C; Aberg, JA ...
Published in: Blood Adv
February 27, 2024

Clonal hematopoiesis of indeterminate potential (CHIP), the clonal expansion of myeloid cells with leukemogenic mutations, results in increased coronary artery disease (CAD) risk. CHIP is more prevalent among people with HIV (PWH), but the risk factors are unknown. CHIP was identified among PWH in REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) using whole-exome sequencing. Logistic regression was used to associate sociodemographic factors and HIV-specific factors with CHIP adjusting for age, sex, and smoking status. In the studied global cohort of 4486 PWH, mean age was 49.9 (standard deviation [SD], 6.4) years; 1650 (36.8%) were female; and 3418 (76.2%) were non-White. CHIP was identified in 223 of 4486 (4.97%) and in 38 of 373 (10.2%) among those aged ≥60 years. Age (odds ratio [OR], 1.07; 95% confidence interval [CI], 1.05-1.09; P < .0001) and smoking (OR, 1.37; 95% CI, 1.14-1.66; P < .001) associated with increased odds of CHIP. Globally, participants outside of North America had lower odds of CHIP including sub-Saharan Africa (OR, 0.57; 95% CI, 0.4-0.81; P = .0019), South Asia (OR, 0.45; 95% CI, 0.23-0.80; P = .01), and Latin America/Caribbean (OR, 0.56; 95% CI, 0.34-0.87; P = .014). Hispanic/Latino ethnicity (OR, 0.38; 95% CI, 0.23-0.54; P = .002) associated with significantly lower odds of CHIP. Among HIV-specific factors, CD4 nadir <50 cells/mm3 associated with a 1.9-fold (95%CI, 1.21-3.05; P = .006) increased odds of CHIP, with the effect being significantly stronger among individuals with short duration of antiretroviral therapy (ART; OR, 4.15; 95% CI, 1.51-11.1; P = .005) (Pinteraction= .0492). Among PWH at low-to-moderate CAD risk on stable ART, smoking, CD4 nadir, North American origin, and non-Hispanic ethnicity associated with increased odds of CHIP. This trial was registered at www.ClinicalTrials.gov as NCT02344290.

Duke Scholars

Published In

Blood Adv

DOI

EISSN

2473-9537

Publication Date

February 27, 2024

Volume

8

Issue

4

Start / End Page

959 / 967

Location

United States

Related Subject Headings

  • Risk Factors
  • North America
  • Middle Aged
  • Male
  • Humans
  • HIV Infections
  • Female
  • Ethnicity
  • Clonal Hematopoiesis
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bhattacharya, R., Uddin, M. M., Patel, A. P., Niroula, A., Finneran, P., Bernardo, R., … Natarajan, P. (2024). Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial. Blood Adv, 8(4), 959–967. https://doi.org/10.1182/bloodadvances.2023011324
Bhattacharya, Romit, Md Mesbah Uddin, Aniruddh P. Patel, Abhishek Niroula, Phoebe Finneran, Rachel Bernardo, Kathleen V. Fitch, et al. “Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial.Blood Adv 8, no. 4 (February 27, 2024): 959–67. https://doi.org/10.1182/bloodadvances.2023011324.
Bhattacharya R, Uddin MM, Patel AP, Niroula A, Finneran P, Bernardo R, et al. Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial. Blood Adv. 2024 Feb 27;8(4):959–67.
Bhattacharya, Romit, et al. “Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial.Blood Adv, vol. 8, no. 4, Feb. 2024, pp. 959–67. Pubmed, doi:10.1182/bloodadvances.2023011324.
Bhattacharya R, Uddin MM, Patel AP, Niroula A, Finneran P, Bernardo R, Fitch KV, Lu MT, Bloomfield GS, Malvestutto C, Aberg JA, Fichtenbaum CJ, Hornsby W, Ribaudo HJ, Libby P, Ebert BL, Zanni MV, Douglas PS, Grinspoon SK, Natarajan P. Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial. Blood Adv. 2024 Feb 27;8(4):959–967.

Published In

Blood Adv

DOI

EISSN

2473-9537

Publication Date

February 27, 2024

Volume

8

Issue

4

Start / End Page

959 / 967

Location

United States

Related Subject Headings

  • Risk Factors
  • North America
  • Middle Aged
  • Male
  • Humans
  • HIV Infections
  • Female
  • Ethnicity
  • Clonal Hematopoiesis
  • 3201 Cardiovascular medicine and haematology